Montis Biosciences
Develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction.
Launch date
Employees
Market cap
-
Enterprise valuation
€33—49m (Dealroom.co estimates Feb 2020.)
Company register number 0730.979.429
Leuven Flemish Brabant (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| EBITDA | (2.4m) | (2.1m) | (3.5m) | - |
| Profit | (2.6m) | (2.3m) | (3.7m) | (4.3m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$9.1m | Seed | ||
| Total Funding | €8.2m | ||
Recent News about Montis Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.